EP1996185A2 - Treatment or prevention of scarring, capsular contractures and/or hyperpigmentation using leukotriene receptor antagonist and vitamin e - Google Patents

Treatment or prevention of scarring, capsular contractures and/or hyperpigmentation using leukotriene receptor antagonist and vitamin e

Info

Publication number
EP1996185A2
EP1996185A2 EP07753480A EP07753480A EP1996185A2 EP 1996185 A2 EP1996185 A2 EP 1996185A2 EP 07753480 A EP07753480 A EP 07753480A EP 07753480 A EP07753480 A EP 07753480A EP 1996185 A2 EP1996185 A2 EP 1996185A2
Authority
EP
European Patent Office
Prior art keywords
vitamin
ltra
alpha
hyperpigmentation
scarring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07753480A
Other languages
German (de)
French (fr)
Inventor
Larry Schlesinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1996185A2 publication Critical patent/EP1996185A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Definitions

  • the present invention is related to a novel use of a combination administration of a leukotriene receptor antagonist and vitamin E to treat or prevent scarring. Additionally, the present invention is related to a novel use of a combination administration of a leukotriene receptor antagonist and vitamin E to treat or prevent capsular contractures, which are a common side effect of breast enhancement surgery. Further, the present invention is related to a novel use of a combination administration of a leukotriene receptor antagonist and vitamin E to treat or prevent hyperpigmentation.
  • Capsular contracture is a known "side effect" commonly related with breast enhancement surgery. Capsular contracture is actually considered to be more of an exaggeration of a normal physiologic response than a side effect, and it is a thickened periprosthetic scar which engulfs the breast implant, thereby resulting in an unnaturally hard breast. Additionally, the shape of the breast can be distorted and physical pain can result from the capsular contracture.
  • People with certain skin types are predisposed to hyperpigmentation after a traumatic event to their skin. This is particularly true for surgical procedures, laser phototherapy, dermabrasion, and other cosmetic procedures that may traumatize the skin.
  • U.S. Patent Application Publication No. US2003/0207932 discloses a topical composition for the prevention of post-traumatic hyperpigmentation, comprising a leukotriene receptor antagonist, melatonin, menthol, benzyl alcohol, polysorbate 80, and trisoleooxymethylmethylamino-1-ethane sulfonic acid.
  • U.S. Patent No. 6,951,869 is directed to a method of preventing or treating scarring or capsular contractures by the administration of a leukotriene receptor antagonist to a subject in need of treatment.
  • the present invention is directed towards a method of treating or preventing capsular contracture, treating or preventing scarring, or treating or preventing hyperpigmentation in a patient in need thereof, comprising administering to the patient at least one leukotriene receptor antagonist (LTRA) and vitamin E 1 in amounts that are therapeutically effective at preventing or treating the aforementioned conditions.
  • LTRA leukotriene receptor antagonist
  • the administration may be sequential, simultaneous, or concomitant, or the administration may be completed over a time period in which one of the agents (i.e., the LTRA or the vitamin E) is administered alone according to a first course of therapy, and thereafter the second agent is administered (with or without continuing the treatment with the first agent) in a second course of therapy.
  • the present invention is directed to administering one or more LTRAs (which include, but are not limited to, acitazanolast, iralukast, montelukast, pranlukast, verlukast, zafiriukast, and zileuton) and vitamin E, to a subject for the treatment and/or prevention of capsular contracture and/or scarring and/or hyperpigmentation.
  • LTRAs include, but are not limited to, acitazanolast, iralukast, montelukast, pranlukast, verlukast, zafiriukast, and zileuton
  • zafiriukast are the most preferred.
  • vitamin E herein includes a substance belonging to the group of ⁇ -, ⁇ -, ⁇ >, ⁇ -, ⁇ 1-, ⁇ 2- and ⁇ -tocophero!s, their dl, d and I forms and their structural analogues, such as tocotrienols; the corresponding derivatives, e.g., esters, produced with organic acids; and mixtures thereof.
  • Preferred vitamin E substances include tocopherols, tocotrienols and tocopherol derivatives with organic acids such as acetic acid, propionic acid, bile acid, lactic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandefic acid, polyethylene glycol succinate and salicylic acid.
  • Particularly preferred vitamin E substances include alpha-tocopherol, alpha-tocopheryl acetate, alpha-tocopheryl acid succinate, alpha-tocopheryl polyethylene glycol 1000 succinate and mixtures thereof.
  • the LTRA and the vitamin E of the present invention may be administered in any conventional form suitable for oral, rectal, topical, parenteral, ocular, pulmonary or nasal administration, and the like, or it may also be administered through inhalation means.
  • Preferred administration is oral and/or topical.
  • Topical administration includes skin application and application to internal body surfaces, including via impregnation on or in an implant.
  • Topical dosage forms include any form suitable for topical, e.g., transdermal, application, and include but are not limited to, gels, solutions, suspensions, lotions, pastes, creams, ointments, aerosols, dusting powders, patches, and the like.
  • administration forms may be presented in unit dosage form and may be prepared by any of the methods well-known in the art of pharmacy.
  • the active agent is typically present in an amount of from 1 to 99% by weight, based upon the total weight of the formulation, for example from 10 to 50% by weight.
  • daily dosage of a LTRA (when the course of therapy calls for an LTRA) may preferably be 5 to 250 mg.
  • Daily dosage of vitamin E when the course of therapy calls for vitamin E may be 10 to 10,000 IU, preferably 500 to 5000 IU.
  • Routes of administration and dosage forms of vitamin E are well-known in the art.
  • LTRA 5 mg, more preferably 10 mg, and most preferably 20 mg of LTRA is administered twice daily.
  • the administration of LTRA is preferably started prior to a surgical procedure, preferably up to 30 days prior.
  • LTRA is preferably administered for at least 7 days following the completion of the surgical procedure.
  • an effective amount of vitamin E preferably 1000 to 5000 IU per day, most preferably about 2000 IU per day, is added to the therapeutic regimen as a second course of therapy.
  • the second course of therapy including the LTRA and vitamin E continues for at least 30 days, preferably for at least 60 days, and most preferably for 90 days or more.
  • the dosage of the LTRA and the vitamin E may be administered in either one single dosage, two dosages, or in more than two dosages per day.
  • the LTRA is administered simultaneous to administration of the vitamin E, e.g M as a single fixed dosage pharmaceutical composition or as separate compositions administered at the same time.
  • the LTRA is administered apart from the administration of the vitamin E, but in a concomitant treatment regime.
  • the LTRA may be administered at one time of the day, orally or topically, and the vitamin E may be administered later or earlier the same day, orally or topically. Or, in one embodiment, the LTRA may be administered daily, while the vitamin E is administered every few days, or vice versa.
  • the precise dosage and schedule for the administration of the LTRA and the vitamin E will vary depending on numerous factors, such as, for example, the route of administration and the seriousness of the condition.
  • the method of preventing scarring and/or capsular contracture and/or hyperpigmentation comprises administering at least one LTRA, and optionally vitamin E, to a patient prior to the formation of a scar and/or a capsular contracture and/or hyperpigmentation.
  • the administration of the at least one LTRA, and optionally vitamin E, to a patient may begin up to one year or more prior to the potential scar and/or capsular contracture and/or hyperpigmentation causing event.
  • the administration of the at least one LTRA, and optionally vitamin E is begun prior to the insertion of the implant.
  • the administration of the at least one LTRA, and optionally vitamin E, to a patient may begin up to one year or more prior to the insertion of the implant.
  • the administration of the at least one LTRA, and optionally vitamin E begins at least 30 days prior to the insertion of the implant.
  • the patient may be administered the at least one LTRA and the vitamin E following the occurrence of the potential scar and/or capsular contracture and/or hyperpigmentation causing event for an indefinite period of time.
  • the administration of the at least one LTRA and vitamin E last no more than one year, preferably no more than six or three months.
  • the administration of the at least one LTRA and vitamin E does not need to be continuous.
  • a patient may be removed from LTRA and Vitamin E administration and later have the at least one LTRA and Vitamin E administered again at a future time.

Abstract

Use of a combination administration of a leukotriene receptor antagonist and vitamin E to prevent or treat scarring and/or capsular contracture and/or hyperpigmentation.

Description

TREATMENT OR PREVENTION OF SCARRING, CAPSULAR CONTRACTURES AND/OR HYPERPIGMENTATION USING LEUKOTRiENE RECEPTOR ANTAGONIST AND VITAMIN E
BACKGROUND OF THE INVENTION
[0001] The present application claims priority from U.S. Provisional
Application Serial No. 60/783,398, filed March 20, 2006.
Field of the Invention
[0002] The present invention is related to a novel use of a combination administration of a leukotriene receptor antagonist and vitamin E to treat or prevent scarring. Additionally, the present invention is related to a novel use of a combination administration of a leukotriene receptor antagonist and vitamin E to treat or prevent capsular contractures, which are a common side effect of breast enhancement surgery. Further, the present invention is related to a novel use of a combination administration of a leukotriene receptor antagonist and vitamin E to treat or prevent hyperpigmentation.
Description of the Related Art
[0003] Scarring is a common side effect resulting from injuries and surgery. Capsular contracture is a known "side effect" commonly related with breast enhancement surgery. Capsular contracture is actually considered to be more of an exaggeration of a normal physiologic response than a side effect, and it is a thickened periprosthetic scar which engulfs the breast implant, thereby resulting in an unnaturally hard breast. Additionally, the shape of the breast can be distorted and physical pain can result from the capsular contracture. [0004] People with certain skin types are predisposed to hyperpigmentation after a traumatic event to their skin. This is particularly true for surgical procedures, laser phototherapy, dermabrasion, and other cosmetic procedures that may traumatize the skin.
[0005] U.S. Patent Application Publication No. US2003/0207932 discloses a topical composition for the prevention of post-traumatic hyperpigmentation, comprising a leukotriene receptor antagonist, melatonin, menthol, benzyl alcohol, polysorbate 80, and trisoleooxymethylmethylamino-1-ethane sulfonic acid.
[0006] U.S. Patent No. 6,951,869 is directed to a method of preventing or treating scarring or capsular contractures by the administration of a leukotriene receptor antagonist to a subject in need of treatment.
SUMMARY OF THE INVENTION
[0007] The present invention is directed towards a method of treating or preventing capsular contracture, treating or preventing scarring, or treating or preventing hyperpigmentation in a patient in need thereof, comprising administering to the patient at least one leukotriene receptor antagonist (LTRA) and vitamin E1 in amounts that are therapeutically effective at preventing or treating the aforementioned conditions. The administration may be sequential, simultaneous, or concomitant, or the administration may be completed over a time period in which one of the agents (i.e., the LTRA or the vitamin E) is administered alone according to a first course of therapy, and thereafter the second agent is administered (with or without continuing the treatment with the first agent) in a second course of therapy. DESCRIPTION OF THE PREFERRED EMBODIMENTS [0008] The present invention is directed to administering one or more LTRAs (which include, but are not limited to, acitazanolast, iralukast, montelukast, pranlukast, verlukast, zafiriukast, and zileuton) and vitamin E, to a subject for the treatment and/or prevention of capsular contracture and/or scarring and/or hyperpigmentation. Of the known LTRAs, zafiriukast, montelukast, and pranlukast are the most preferred. Of these three compounds, zafiriukast and montelukast are more preferred, and zafiriukast is the most preferred. [0009] The term "vitamin E" herein includes a substance belonging to the group of α-, β-, γ>, δ-, ζ1-, ζ2- and η-tocophero!s, their dl, d and I forms and their structural analogues, such as tocotrienols; the corresponding derivatives, e.g., esters, produced with organic acids; and mixtures thereof. Preferred vitamin E substances include tocopherols, tocotrienols and tocopherol derivatives with organic acids such as acetic acid, propionic acid, bile acid, lactic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandefic acid, polyethylene glycol succinate and salicylic acid. Particularly preferred vitamin E substances include alpha-tocopherol, alpha-tocopheryl acetate, alpha-tocopheryl acid succinate, alpha-tocopheryl polyethylene glycol 1000 succinate and mixtures thereof.
[00010] The LTRA and the vitamin E of the present invention may be administered in any conventional form suitable for oral, rectal, topical, parenteral, ocular, pulmonary or nasal administration, and the like, or it may also be administered through inhalation means. Preferred administration is oral and/or topical. Topical administration includes skin application and application to internal body surfaces, including via impregnation on or in an implant. Topical dosage forms include any form suitable for topical, e.g., transdermal, application, and include but are not limited to, gels, solutions, suspensions, lotions, pastes, creams, ointments, aerosols, dusting powders, patches, and the like. These administration forms may be presented in unit dosage form and may be prepared by any of the methods well-known in the art of pharmacy. The active agent is typically present in an amount of from 1 to 99% by weight, based upon the total weight of the formulation, for example from 10 to 50% by weight.
[00011] Information on dosing, administration and dosage forms for the one or more LTRAs can be found, e.g., in U.S. Patent No. 6,951,869, hereby incorporated by reference in its entirety. For example, daily dosage of a LTRA (when the course of therapy calls for an LTRA) may preferably be 5 to 250 mg. Daily dosage of vitamin E (when the course of therapy calls for vitamin E) may be 10 to 10,000 IU, preferably 500 to 5000 IU. Routes of administration and dosage forms of vitamin E are well-known in the art. [00012] Treating a subject with a combined therapy of LTRA and vitamin E will have a synergistic effect that is unexpected over treatment with either agent alone.
[00013] In one preferred embodiment, 5 mg, more preferably 10 mg, and most preferably 20 mg of LTRA is administered twice daily. The administration of LTRA is preferably started prior to a surgical procedure, preferably up to 30 days prior. LTRA is preferably administered for at least 7 days following the completion of the surgical procedure. [00014] In one embodiment, on or near the 8th post-surgical day, an effective amount of vitamin E, preferably 1000 to 5000 IU per day, most preferably about 2000 IU per day, is added to the therapeutic regimen as a second course of therapy.
[00015] In one embodiment, once the second course of therapy including the LTRA and vitamin E is begun, the second course continues for at least 30 days, preferably for at least 60 days, and most preferably for 90 days or more. [00016] The dosage of the LTRA and the vitamin E may be administered in either one single dosage, two dosages, or in more than two dosages per day. In one embodiment, for at least one course of therapy the LTRA is administered simultaneous to administration of the vitamin E, e.gM as a single fixed dosage pharmaceutical composition or as separate compositions administered at the same time. In another embodiment, for at least one course of therapy the LTRA is administered apart from the administration of the vitamin E, but in a concomitant treatment regime. For example, the LTRA may be administered at one time of the day, orally or topically, and the vitamin E may be administered later or earlier the same day, orally or topically. Or, in one embodiment, the LTRA may be administered daily, while the vitamin E is administered every few days, or vice versa. One skilled in the art with the benefit of the present disclosure will understand that the precise dosage and schedule for the administration of the LTRA and the vitamin E will vary depending on numerous factors, such as, for example, the route of administration and the seriousness of the condition. [00017] Preferably, the method of preventing scarring and/or capsular contracture and/or hyperpigmentation comprises administering at least one LTRA, and optionally vitamin E, to a patient prior to the formation of a scar and/or a capsular contracture and/or hyperpigmentation. The administration of the at least one LTRA, and optionally vitamin E, to a patient may begin up to one year or more prior to the potential scar and/or capsular contracture and/or hyperpigmentation causing event.
[00018] Additionally, if the patient is receiving an implant, it is preferred that the administration of the at least one LTRA, and optionally vitamin E, is begun prior to the insertion of the implant. The administration of the at least one LTRA, and optionally vitamin E, to a patient may begin up to one year or more prior to the insertion of the implant. Preferably, the administration of the at least one LTRA, and optionally vitamin E, begins at least 30 days prior to the insertion of the implant.
[00019] The patient may be administered the at least one LTRA and the vitamin E following the occurrence of the potential scar and/or capsular contracture and/or hyperpigmentation causing event for an indefinite period of time. However, it is preferred that the administration of the at least one LTRA and vitamin E last no more than one year, preferably no more than six or three months.
[00020] The administration of the at least one LTRA and vitamin E does not need to be continuous. In other words, a patient may be removed from LTRA and Vitamin E administration and later have the at least one LTRA and Vitamin E administered again at a future time.
[00021] All references cited herein are incorporated by reference in their entirety.

Claims

What is claimed is:
1. A method of treating or preventing capsular contracture, and/or scarring, and/or hyperpigmentation in a patient in need thereof, comprising administering to the patient at least one leukotriene receptor antagonist (LTRA) and vitamin E, in amounts that are therapeutically effective at treating or preventing the capsular contracture, and/or scarring, and/or hyperpigmentation in the patient.
2. The method of claim 1 , wherein the LTRA is selected from the group consisting of acitazanolast, iralukast, montelukast, pranlukast, verlukast, zafirlukast, and zileύton.
3. The method of claim 1 or 2, wherein the vitamin E is selected from the group consisting of alpha-tocopherol, alpha-tocopheryl acetate, alpha- tocopheryl acid succinate, alpha-tocopheryl polyethylene glycol 1000 succinate and mixtures thereof.
4. The method of any one of claims 1-3, wherein the LTRA and/or the vitamin E is administered oraKy or topically.
5. A method of preventing scarring and/or capsular contracture and/or hyperpigmentation in a patient in need thereof, comprising administering at least one leukotriene receptor antagonist (LTRA) and vitamin E to. the patient in amounts that are therapeutically effective, prior to the formation of a scar and/or a capsular contracture and/or hyperpigmentation.
6. The method of claim 5, wherein the LTRA is selected from the group consisting of acitazanolast, iralukast, montelukast, pranlukast, verlukast, zafirlukast, and zileuton.
7. The method of claim 5 or 6, wherein the vitamin E is selected from the group consisting of alpha-tocopherol, alpha-tocopheryl acetate, alpha- tocopheryl acid succinate, alpha-tocopheryl polyethylene glycol 1000 succinate and mixtures thereof.
8. the method of any one of claims 5-7, wherein the LTRA and/or the vitamin E is administered orally or topically.
9. A method of treating or preventing scarring and/or capsular contracture in a patient receiving a breast implant, comprising providing the patient with a breast implant coated with at least one leukotriene receptor antagonist (LTRA) and vitamin E, in amounts that are therapeutically effective at treating or preventing the scarring and/or capsular contracture.
10. The method of claim 9, wherein the LTRA is selected from the group consisting of acitazanolast, iralukast, montelukast, pranlukast, verlukast, zafirlukast, and zileuton.
11. The method of claim 9 or 10, wherein the vitamin E is selected from the group consisting of alpha-tocopherol, alpha-tocopheryl acetate, alpha- tocopheryl add succinate, alpha-tocopheryl polyethylene glycol 1000 succinate and mixtures thereof.
EP07753480A 2006-03-20 2007-03-20 Treatment or prevention of scarring, capsular contractures and/or hyperpigmentation using leukotriene receptor antagonist and vitamin e Withdrawn EP1996185A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78339806P 2006-03-20 2006-03-20
PCT/US2007/006854 WO2007109248A2 (en) 2006-03-20 2007-03-20 Treatment or prevention of scarring, capsular contractures and/or hyperpigmentation using leukotriene receptor antagonist and vitamin e

Publications (1)

Publication Number Publication Date
EP1996185A2 true EP1996185A2 (en) 2008-12-03

Family

ID=38523041

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07753480A Withdrawn EP1996185A2 (en) 2006-03-20 2007-03-20 Treatment or prevention of scarring, capsular contractures and/or hyperpigmentation using leukotriene receptor antagonist and vitamin e

Country Status (4)

Country Link
EP (1) EP1996185A2 (en)
AU (1) AU2007227286A1 (en)
CA (1) CA2646969A1 (en)
WO (1) WO2007109248A2 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337076B1 (en) * 1999-11-17 2002-01-08 Sg Licensing Corporation Method and composition for the treatment of scars
US6951869B2 (en) * 2002-02-26 2005-10-04 Schlesinger Stephen L Use of leukotriene receptor antagonist for treatment of scarring
US20050208002A1 (en) * 2002-03-06 2005-09-22 Eiko Kato Whitening cosmetic composition
KR20050003417A (en) * 2002-05-09 2005-01-10 쇼와 덴코 가부시키가이샤 Skin Whitening External Preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007109248A3 *

Also Published As

Publication number Publication date
WO2007109248A3 (en) 2008-03-20
CA2646969A1 (en) 2007-09-27
AU2007227286A1 (en) 2007-09-27
WO2007109248A2 (en) 2007-09-27

Similar Documents

Publication Publication Date Title
JP6112867B2 (en) Treatment of loss of touch with saxitoxin derivatives
WO2005087195A3 (en) Novel compositions for topical delivery
SK14762003A3 (en) Skin-permeable composition comprising a selective cyclooxygenase- 2 inhibitor a monohydric alcohol
ZA200007752B (en) Compounds having IgE affecting properties.
EP2481747A1 (en) Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
KR20040049849A (en) Compositions for treatment of common cold
AU2006245564A1 (en) Pharmaceutical formulation of apomorphine for buccal administration
CN115916184A (en) Transdermal and/or topical pharmaceutical formulations for the treatment of chronic pain comprising cannabidiol and/or tetrahydrocannabinol
US11826330B2 (en) Compounded compositions and methods for treating pain
EP3677265A1 (en) Composition for preventing or treating sleep disorders
JP2003534359A (en) Use of a biguanide derivative for producing a medicament having a scar-forming action
RU2561871C2 (en) Opioid receptor antagonist (naltrexone) applicable in therapy of herpes zoster
EP4003299A1 (en) Treatment of skin disorders with topical tapinarof-egfr inhibitor compositions
AU2002366567B2 (en) Use of an H1 antagonist and a safe steroid to treat rhinitis
Lyseng-Williamson Fentanyl pectin nasal spray: in breakthrough pain in opioid-tolerant adults with cancer
JP2008531640A (en) Antifungal composition comprising sertaconazole and hydrocortisone and / or antibacterial quinolone compound
JP2001510153A (en) Spray formulation of antihyperalgesic opiates and method of treating topical hyperalgesic symptoms and associated pruritus
WO2008073779A2 (en) Compositions and methods for treating seizures
O'Hanlon et al. Preoperative application of piroxicam gel compared to a local anaesthetic field block for postoperative analgesia
KR20010071319A (en) Minoxidil Compositions for External Use
PT1482938E (en) Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist
US20090281143A1 (en) Dose Reduction of a Cannabinoid CB1 Receptor Antagonist in the Treatment of Overweight or Obesity
EP1996185A2 (en) Treatment or prevention of scarring, capsular contractures and/or hyperpigmentation using leukotriene receptor antagonist and vitamin e
JP2004091473A (en) Therapeutic agent for improving chromatosis
CA2443235A1 (en) Pharmaceutical compositions comprising ascomycin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081007

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091001